A Phase III, Randomised, Open-label Study Comparing the Combination of the BRAF Inhibitor, Dabrafenib and the MEK Inhibitor, Trametinib to the BRAF Inhibitor Vemurafenib in Subjects With Unresectable (Stage IIIc) or Metastatic (Stage IV) BRAF V600E/K Mutation Positive Cutaneous Melanoma

Inclusion Criteria:

- >= 18 years of age

- Stage IIIc or Stage IV BRAF V600E/K cutaneous melanoma

- Measurable disease according to RECIST 1.1

- Women of childbearing potential with negative serum pregnancy test prior to
randomisation

- Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1

- Adequate baseline organ function

Exclusion Criteria:

- Any prior use of a BRAF or MEK inhibitor

- Prior systemic anti-cancer treatment in the advanced or metastatic setting; prior
systemic treatment in the adjuvant setting is allowed

- History of another malignancy (except subjects who have been disease free for 3 years
or with a history of completely resected non-melanoma skin cancer)

- Known HIV, HBV, HCV infection (except chronic or cleared HBV and HCV infection which
will be allowed)

- Brain metastases (except if all known lesions were previously treated with surgery or
stereotactic radiosurgery and lesions, if still present, are confirmed stable for >=
12 weeks prior to randomisation or if no longer present are confirmed no evidence of
disease for >= 12 weeks, and are asymptomatic with no corticosteroid requirements for
>= 4 weeks prior to randomisation, and no enzyme inducing anticonvulsants for >= 4
weeks prior to randomisation

- History or evidence of cardiovascular risk (LVEF < LLN; QTcB >= 480 msec; blood
pressure or systolic >=140 mmHg or diastolic >= 90 mmHg which cannot be controlled by
anti-hypertensive therapy)

- History or current evidence/risk of retinal vein occlusion (RVO) or central serous
retinopathy (CSR)